PPARγ: A molecular link between systemic metabolic disease and benign prostate hyperplasia

Ming Jiang, Douglas W. Strand, Omar E. Franco, Peter E. Clark, Simon W. Hayward

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


The emergent epidemic of metabolic syndrome and its complex list of sequelae mandate a more thorough understanding of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) in the context of systemic metabolic disease. Here we discuss the nature and origins of BPH, examine its role as a component of LUTS and review retrospective clinical studies that have drawn associations between BPH/LUTS and type II diabetes, inflammation and dyslipidemia. PPARγ signaling, which sits at the nexus of systemic metabolic disease and BPH/LUTS through its regulation of inflammation and insulin resistance, is proposed as a candidate for molecular manipulation in regard to BPH/LUTS. Finally, we introduce new cell and animal models that are being used to study the consequences of obesity, diabetes and inflammation on benign prostatic growth.

Original languageEnglish (US)
Pages (from-to)220-236
Number of pages17
Issue number4-5
StatePublished - Nov 2011


  • BPH
  • Co-morbidities
  • Inflammation
  • LUTS
  • Metabolism
  • PPARγ

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'PPARγ: A molecular link between systemic metabolic disease and benign prostate hyperplasia'. Together they form a unique fingerprint.

Cite this